Skip to main content
NCBI home page
Canadian Medical Association Journal logoLink to Canadian Medical Association Journal
. 1983 Sep 1;129(5):424-8, 432.

Vasodilators.

T T Zsotér
PMCID: PMC1875176  PMID: 6349763

Abstract

This article reviews the types, mechanisms of action and therapeutic applications of currently used vasodilators. Vasodilators have little value if there is vascular obstruction but are effective in the treatment of systemic hypertension and of myocardial ischemia and heart failure. Since the various groups of vasodilators have widely different actions on the coronary arteries, the peripheral arterial circulation and venous tone, an understanding of the specific modes of action and of the systemic effects of these drugs is essential if they are to be used appropriately and their side effects minimized.

Full text

PDF
424

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Axelsson K. L., Wikberg J. E., Andersson R. G. Relationship between nitroglycerin, cyclic GMP and relaxation of vascular smooth muscle. Life Sci. 1979 May 7;24(19):1779–1786. doi: 10.1016/0024-3205(79)90067-5. [DOI] [PubMed] [Google Scholar]
  2. Bennett W. M., Muther R. S., Parker R. A., Feig P., Morrison G., Golper T. A., Singer I. Drug therapy in renal failure: dosing guidelines for adults. Part II: sedatives, hypnotics, and tranquilizers; cardiovascular, antihypertensive, and diuretic agents; miscellaneous agents. Ann Intern Med. 1980 Aug;93(2):286–325. doi: 10.7326/0003-4819-111-3-286. [DOI] [PubMed] [Google Scholar]
  3. Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs. 1977 Sep;14(3):163–197. doi: 10.2165/00003495-197714030-00002. [DOI] [PubMed] [Google Scholar]
  4. Chatterjee K., Parmley W. W. Vasodilator therapy for chronic heart failure. Annu Rev Pharmacol Toxicol. 1980;20:475–512. doi: 10.1146/annurev.pa.20.040180.002355. [DOI] [PubMed] [Google Scholar]
  5. Chatterjee K., Rouleau J. L., Parmley W. W. Haemodynamic and myocardial metabolic effects of captopril in chronic heart failure. Br Heart J. 1982 Mar;47(3):233–238. doi: 10.1136/hrt.47.3.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Church J., Zsotér T. T. Calcium antagonistic drugs. Mechanism of action. Can J Physiol Pharmacol. 1980 Mar;58(3):254–264. doi: 10.1139/y80-044. [DOI] [PubMed] [Google Scholar]
  7. Cody R. J., Franklin K. W., Kluger J., Laragh J. H. Sympathetic responsiveness and plasma norepinephrine during therapy of chronic congestive heart failure with captopril. Am J Med. 1982 May;72(5):791–797. doi: 10.1016/0002-9343(82)90547-2. [DOI] [PubMed] [Google Scholar]
  8. Colucci W. S. Alpha-adrenergic receptor blockade with prazosin. Consideration of hypertension, heart failure, and potential new applications. Ann Intern Med. 1982 Jul;97(1):67–77. doi: 10.7326/0003-4819-97-1-67. [DOI] [PubMed] [Google Scholar]
  9. Constantine J. W., Hess H. J. The cardiovascular effects of trimazosin. Eur J Pharmacol. 1981 Sep 11;74(2-3):227–238. doi: 10.1016/0014-2999(81)90535-5. [DOI] [PubMed] [Google Scholar]
  10. Curtiss C., Cohn J. N., Vrobel T., Franciosa J. A. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation. 1978 Nov;58(5):763–770. doi: 10.1161/01.cir.58.5.763. [DOI] [PubMed] [Google Scholar]
  11. Franciosa J. A., Pierpont G., Cohn J. N. Hemodynamic improvement after oral hydralazine in left ventricular failure: a comparison with nitroprusside infusion in 16 patients. Ann Intern Med. 1977 Apr;86(4):388–393. doi: 10.7326/0003-4819-86-4-388. [DOI] [PubMed] [Google Scholar]
  12. Guazzi M. D., Fiorentini C., Olivari M. T., Bartorelli A., Necchi G., Polese A. Short- and long-term efficacy of a calcium-antagonistic agent (nifedipine) combined with methyldopa in the treatment of severe hypertension. Circulation. 1980 May;61(5):913–919. doi: 10.1161/01.cir.61.5.913. [DOI] [PubMed] [Google Scholar]
  13. Imai Y., Abe K., Sato M., Haruyama T., Hiwatari M., Goto T., Sato K., Kasai Y., Tajima J., Yoshinaga K. Evaluation of the chronotropic property of captopril in hypertensive patients. Am Heart J. 1982 Dec;104(6):1339–1345. doi: 10.1016/0002-8703(82)90165-x. [DOI] [PubMed] [Google Scholar]
  14. Kanada S. A., Kanada D. J., Hutchinson R. A., Wu D. Angina-like syndrome with diazoxide therapy for hypertensive crisis. Ann Intern Med. 1976 Jun;84(6):696–699. doi: 10.7326/0003-4819-84-6-696. [DOI] [PubMed] [Google Scholar]
  15. Kimura E., Kishida H. Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan. Circulation. 1981 Apr;63(4):844–848. doi: 10.1161/01.cir.63.4.844. [DOI] [PubMed] [Google Scholar]
  16. Klotman P. E., Grim C. E., Weinberger M. H., Judson W. E. The effects of minoxidil on pulmonary and systemic hemodynamics in hypertensive man. Circulation. 1977 Feb;55(2):394–400. doi: 10.1161/01.cir.55.2.394. [DOI] [PubMed] [Google Scholar]
  17. Kripalani K. J., McKinstry D. N., Singhvi S. M., Willard D. A., Vukovich R. A., Migdalof B. H. Disposition of captopril in normal subjects. Clin Pharmacol Ther. 1980 May;27(5):636–641. doi: 10.1038/clpt.1980.90. [DOI] [PubMed] [Google Scholar]
  18. Kuwajima I., Ueda K., Kamata C., Matsushita S., Kuramoto K., Murakami M., Hada Y. A study on the effects of nifedipine in hypertensive crises and severe hypertension. Jpn Heart J. 1978 Jul;19(4):455–467. doi: 10.1536/ihj.19.455. [DOI] [PubMed] [Google Scholar]
  19. Langer S. Z., Cavero I., Massingham R. Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension. 1980 Jul-Aug;2(4):372–382. doi: 10.1161/01.hyp.2.4.372. [DOI] [PubMed] [Google Scholar]
  20. McAllister R. G., Jr Clinical pharmacology of slow channel blocking agents. Prog Cardiovasc Dis. 1982 Sep-Oct;25(2):83–102. doi: 10.1016/0033-0620(82)90022-6. [DOI] [PubMed] [Google Scholar]
  21. McGregor M., Fam W. M. Regulation of coronary blood flow. Bull N Y Acad Med. 1966 Nov;42(11):940–950. [PMC free article] [PubMed] [Google Scholar]
  22. McLean A. J., du Souich P., Barron K. W., Briggs A. H. Interaction of hydralazine with tension development and mechanisms of calcium accumulation in K+-stimulated rabbit aortic strips. J Pharmacol Exp Ther. 1978 Oct;207(1):40–48. [PubMed] [Google Scholar]
  23. Miller R. R., Fennell W. H., Young J. B., Palomo A. R., Quinones M. A. Differential systemic arterial and venous actions and consequent cardiac effects of vasodilator drugs. Prog Cardiovasc Dis. 1982 Mar-Apr;24(5):353–374. doi: 10.1016/0033-0620(82)90019-6. [DOI] [PubMed] [Google Scholar]
  24. Nakashima Y., Fouad F. M., Tarazi R. C. Long-term captopril therapy in congestive heart failure: serial hemodynamic and echocardiographic changes. Am Heart J. 1982 Oct;104(4 Pt 1):827–833. doi: 10.1016/0002-8703(82)90019-9. [DOI] [PubMed] [Google Scholar]
  25. Ogasawara B., Ogawa K., Hayashi H., Sassa H. Plasma renin activity and plasma concentrations of norepinephrine and cyclic nucleotides in heart failure after prazosin. Clin Pharmacol Ther. 1981 Apr;29(4):464–471. doi: 10.1038/clpt.1981.64. [DOI] [PubMed] [Google Scholar]
  26. Olivari M. T., Bartorelli C., Polese A., Fiorentini C., Moruzzi P., Guazzi M. D. Treatment of hypertension with nifedipine, a calcium antagonistic agent. Circulation. 1979 May;59(5):1056–1062. doi: 10.1161/01.cir.59.5.1056. [DOI] [PubMed] [Google Scholar]
  27. Packer M., Frishman W. H. Verapamil therapy for stable and unstable angina pectoris: calcium channel antagonists in perspective. Am J Cardiol. 1982 Oct;50(4):881–885. doi: 10.1016/0002-9149(82)91249-8. [DOI] [PubMed] [Google Scholar]
  28. Packer M., Le Jemtel T. H. Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure. Prog Cardiovasc Dis. 1982 Jan-Feb;24(4):275–292. doi: 10.1016/0033-0620(82)90006-8. [DOI] [PubMed] [Google Scholar]
  29. Raine A. E., Ledingham J. G. Clinical experience with captopril in the treatment of severe drug-resistant hypertension. Am J Cardiol. 1982 Apr 21;49(6):1475–1479. doi: 10.1016/0002-9149(82)90363-0. [DOI] [PubMed] [Google Scholar]
  30. Rouleau J. L., Chatterjee K., Benge W., Parmley W. W., Hiramatsu B. Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study. Circulation. 1982 Apr;65(4):671–678. doi: 10.1161/01.cir.65.4.671. [DOI] [PubMed] [Google Scholar]
  31. Ruedy J. Verapamil. Clin Invest Med. 1981;4(2):129–147. [PubMed] [Google Scholar]
  32. Sato M., Nagao T., Yamaguchi I., Nakajima H., Kiyomoto A. Pharmacological studies on a new l,5-benzothiazepine derivative (CRD-401). Arzneimittelforschung. 1971 Sep;21(9):1338–1343. [PubMed] [Google Scholar]
  33. Schroeder J. S., Feldman R. L., Giles T. D., Friedman M. J., DeMaria A. N., Kinney E. L., Mallon S. M., Pit B., Meyer R., Basta L. L. Multiclinic controlled trial of diltiazem for Prinzmetal's angina. Am J Med. 1982 Feb;72(2):227–232. doi: 10.1016/0002-9343(82)90814-2. [DOI] [PubMed] [Google Scholar]
  34. Slutsky R. Hemodynamic effects of inhaled terbutaline in congestive heart failure patients without lung disease: beneficial cardiotonic and vasodilator beta-agonist properties evaluated by ventricular catheterization and radionuclide angiography. Am Heart J. 1981 May;101(5):556–560. doi: 10.1016/0002-8703(81)90221-0. [DOI] [PubMed] [Google Scholar]
  35. Stein L., Henry D. P., Weinberger M. H. Increase in plasma norepinephrine during prazosin therapy for chronic congestive heart failure. Am J Med. 1981 Apr;70(4):825–832. doi: 10.1016/0002-9343(81)90539-8. [DOI] [PubMed] [Google Scholar]
  36. Stone P. H., Antman E. M., Muller J. E., Braunwald E. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann Intern Med. 1980 Dec;93(6):886–904. doi: 10.7326/0003-4819-93-6-886. [DOI] [PubMed] [Google Scholar]
  37. Subramanian B., Bowles M. J., Davies A. B., Raftery E. B. Combined therapy with verapamil and propranolol in chronic stable angina. Am J Cardiol. 1982 Jan;49(1):125–132. doi: 10.1016/0002-9149(82)90286-7. [DOI] [PubMed] [Google Scholar]
  38. Swartz S. L., Williams G. H. Angiotensin-converting enzyme inhibition and prostaglandins. Am J Cardiol. 1982 Apr 21;49(6):1405–1409. doi: 10.1016/0002-9149(82)90351-4. [DOI] [PubMed] [Google Scholar]
  39. Thadani U., Manyari D., Parker J. O., Fung H. L. Tolerance to the circulatory effects of oral isosorbide dinitrate. Rate of development and cross-tolerance to glyceryl trinitrate. Circulation. 1980 Mar;61(3):526–535. doi: 10.1161/01.cir.61.3.526. [DOI] [PubMed] [Google Scholar]
  40. Towart R., Perzborn E. Nimodipine inhibits carbocyclic thromboxane-induced contractions of cerebral arteries. Eur J Pharmacol. 1981 Jan 16;69(2):213–215. doi: 10.1016/0014-2999(81)90417-9. [DOI] [PubMed] [Google Scholar]
  41. Zsotér T. T., Church J. G. Calcium antagonists. Pharmacodynamic effects and mechanism of action. Drugs. 1983 Feb;25(2):93–112. doi: 10.2165/00003495-198325020-00001. [DOI] [PubMed] [Google Scholar]
  42. Zsotér T. T., Henein N. F., Wolchinsky C. The effect of sodium nitroprusside on the uptake and efflux of 45Ca from rabbit and rat vessels. Eur J Pharmacol. 1977 Sep 1;45(1):7–12. doi: 10.1016/0014-2999(77)90052-8. [DOI] [PubMed] [Google Scholar]
  43. van Breemen C., Hwang O., Meisheri K. D. The mechanism of inhibitory action of diltiazem on vascular smooth muscle contractility. J Pharmacol Exp Ther. 1981 Aug;218(2):459–463. [PubMed] [Google Scholar]

Articles from Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES